iBio, Inc. announced it has commenced an underwritten public offering of pre-funded warrants and Series G and Series H warrants.
The offering is subject to market conditions with no assurance of completion or specific terms.
Proceeds from the offering will advance preclinical cardiometabolic programs and other pipeline assets.
Proposed Public Offering
iBio is offering pre-funded warrants and Series G and Series H warrants in a public offering.
Use of Proceeds
Net proceeds will fund advancement of preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, among other pipeline assets.
Lead Bookrunning Manager
Leerink Partners is the lead bookrunning manager for the offering.
- The offering will support the development of iBio's cardiometabolic programs and accelerate progress in the company's pipeline assets.
- With the support from the offering, iBio aims to unlock new possibilities in precision medicine and address unmet medical needs.
- The involvement of financial advisors and bookrunning managers indicates a strategic approach to financing and future growth.
iBio's proposed public offering marks a strategic move to fund key development milestones and advance its innovative biopharmaceutical programs. The company's focus on precision medicine and breakthrough treatments shows promise for future growth and impact in the healthcare sector.